Associated Papers
Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC.
Oh SY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
36269795 (PubMed )
Supplement: ccr-22-2180_supplementary_table_1_suppts1.xlsx › WES-Somatic_Mutation
Select a paper to view details